These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 11584728

  • 1. Comparison of safety and immunogenicity of a Vi polysaccharide typhoid vaccine with a whole-cell killed vaccine in Malaysian Air Force recruits.
    Panchanathan V, Kumar S, Yeap W, Devi S, Ismail R, Sarijan S, Sam SM, Jusoh Z, Nordin S, Leboulleux D, Pang T.
    Bull World Health Organ; 2001; 79(9):811-7. PubMed ID: 11584728
    [Abstract] [Full Text] [Related]

  • 2. Revaccination with locally-produced vi typhoid polysaccharide vaccine among chinese school-aged children: safety and immunogenicity findings.
    Zhou WZ, Koo HW, Wang XY, Zhang J, Park JK, Zhu F, Deen J, Acosta CJ, Chen Y, Wang H, Galindo CM, Ochiai L, Park T, von Seidlein L, Xu ZY, Clemens JD.
    Pediatr Infect Dis J; 2007 Nov; 26(11):1001-5. PubMed ID: 17984806
    [Abstract] [Full Text] [Related]

  • 3. Immunogenicity and safety of Vi capsular polysaccharide typhoid vaccine in healthy persons in Korea.
    Lim SM, Jung HS, Kim MJ, Park DW, Kim WJ, Cheong HJ, Park SC, Lee KC, Shin YK, Tan HK, Kim SL, Sohn JW.
    J Microbiol Biotechnol; 2007 Apr; 17(4):611-5. PubMed ID: 18051272
    [Abstract] [Full Text] [Related]

  • 4. A cluster-randomized effectiveness trial of Vi typhoid vaccine in India.
    Sur D, Ochiai RL, Bhattacharya SK, Ganguly NK, Ali M, Manna B, Dutta S, Donner A, Kanungo S, Park JK, Puri MK, Kim DR, Dutta D, Bhaduri B, Acosta CJ, Clemens JD.
    N Engl J Med; 2009 Jul 23; 361(4):335-44. PubMed ID: 19625715
    [Abstract] [Full Text] [Related]

  • 5. A Japanese study to assess immunogenicity and safety of a typhoid Vi polysaccharide vaccine.
    Miyazu M, Kikuchi H, Hamada A, Fukushima S, Ouchi K, Bosch Castells V, Mihara H, Bonnet MC.
    Vaccine; 2015 Nov 27; 33(48):6697-702. PubMed ID: 26518404
    [Abstract] [Full Text] [Related]

  • 6. Safety of Typhim Vi vaccine in a postmarketing observational study.
    Marcus LC, Froeschle JE, Hill DR, Wolfe MS, Maus D, Connor B, Acosta AM, Rensimer ER, Roberts A, Dardick K.
    J Travel Med; 2007 Nov 27; 14(6):386-91. PubMed ID: 17995534
    [Abstract] [Full Text] [Related]

  • 7. Typhim Vi vaccine against typhoid fever: a clinical trial in Kenya.
    Mirza NB, Wamola IA, Estambale BA, Mbithi E, Poillet M.
    East Afr Med J; 1995 Mar 27; 72(3):162-4. PubMed ID: 7796767
    [Abstract] [Full Text] [Related]

  • 8. Duration of Vi antibodies in participants vaccinated with Typhim Vi (Typhoid Vi polysaccharide vaccine) in an area not endemic for typhoid fever.
    Froeschle JE, Decker MD.
    Vaccine; 2010 Feb 10; 28(6):1451-3. PubMed ID: 20003920
    [Abstract] [Full Text] [Related]

  • 9. [Study on the safety and immunogenicity of group A + C meningococcal polysaccharide vaccine].
    He L, Li RC, Li YN, Huang YN, Yao Q, Yuan ZL, Li FX, Cui XL, Nong Y, Yang M.
    Zhonghua Liu Xing Bing Xue Za Zhi; 2007 May 10; 28(5):422-5. PubMed ID: 17877165
    [Abstract] [Full Text] [Related]

  • 10. Efficacy and safety of vi-tetanus toxoid conjugated typhoid vaccine (PedaTyph™) in Indian children: School based cluster randomized study.
    Mitra M, Shah N, Ghosh A, Chatterjee S, Kaur I, Bhattacharya N, Basu S.
    Hum Vaccin Immunother; 2016 Apr 02; 12(4):939-45. PubMed ID: 26901576
    [Abstract] [Full Text] [Related]

  • 11. Safety and immunogenicity of a new inactivated hepatitis A vaccine in concurrent administration with a typhoid fever vaccine or a typhoid fever + yellow fever vaccine.
    Dumas R, Forrat R, Lang J, Farinelli T, Loutan L.
    Adv Ther; 1997 Apr 02; 14(4):160-7. PubMed ID: 10174195
    [Abstract] [Full Text] [Related]

  • 12. Immune responses to an oral typhoid vaccine strain that is modified to constitutively express Vi capsular polysaccharide.
    Tacket CO, Pasetti MF, Sztein MB, Livio S, Levine MM.
    J Infect Dis; 2004 Aug 01; 190(3):565-70. PubMed ID: 15243933
    [Abstract] [Full Text] [Related]

  • 13. A new typhoid vaccine composed of the Vi capsular polysaccharide.
    Plotkin SA, Bouveret-Le Cam N.
    Arch Intern Med; 1995 Nov 27; 155(21):2293-9. PubMed ID: 7487253
    [Abstract] [Full Text] [Related]

  • 14. A phase 1 randomized safety, reactogenicity, and immunogenicity study of Typhax: A novel protein capsular matrix vaccine candidate for the prevention of typhoid fever.
    Cartee RT, Thanawastien A, Griffin Iv TJ, Mekalanos JJ, Bart S, Killeen KP.
    PLoS Negl Trop Dis; 2020 Jan 27; 14(1):e0007912. PubMed ID: 31905228
    [Abstract] [Full Text] [Related]

  • 15. Safety and immunogenicity of a Vi polysaccharide-tetanus toxoid conjugate vaccine (Typbar-TCV) in healthy infants, children, and adults in typhoid endemic areas: a multicenter, 2-cohort, open-label, double-blind, randomized controlled phase 3 study.
    Mohan VK, Varanasi V, Singh A, Pasetti MF, Levine MM, Venkatesan R, Ella KM.
    Clin Infect Dis; 2015 Aug 01; 61(3):393-402. PubMed ID: 25870324
    [Abstract] [Full Text] [Related]

  • 16. Effectiveness of Vi capsular polysaccharide typhoid vaccine among children: a cluster randomized trial in Karachi, Pakistan.
    Khan MI, Soofi SB, Ochiai RL, Habib MA, Sahito SM, Nizami SQ, Acosta CJ, Clemens JD, Bhutta ZA, DOMI Typhoid Karachi Vi Effectiveness Study Group.
    Vaccine; 2012 Aug 03; 30(36):5389-95. PubMed ID: 22721899
    [Abstract] [Full Text] [Related]

  • 17. Efficacy trial of Vi polysaccharide vaccine against typhoid fever in south-western China.
    Yang HH, Wu CG, Xie GZ, Gu QW, Wang BR, Wang LY, Wang HF, Ding ZS, Yang Y, Tan WS, Wang WY, Wang XC, Qin M, Wang JH, Tang HA, Jiang XM, Li YH, Wang ML, Zhang SL, Li GL.
    Bull World Health Organ; 2001 Aug 03; 79(7):625-31. PubMed ID: 11477965
    [Abstract] [Full Text] [Related]

  • 18. Cross-reactive immune response elicited by parenteral Vi polysaccharide typhoid vaccine against non-typhoid Salmonellae.
    Pakkanen SH, Kantele JM, Herzog C, Kantele A.
    Vaccine; 2014 Jan 23; 32(5):544-51. PubMed ID: 24342246
    [Abstract] [Full Text] [Related]

  • 19. Immunogenicity of Vi capsular polysaccharide vaccine evaluated for three years in Korea.
    Kim YR, Yoo JH, Hur JK, Kang JH, Shin WS, Kang MW.
    J Korean Med Sci; 1995 Oct 23; 10(5):314-7. PubMed ID: 8750055
    [Abstract] [Full Text] [Related]

  • 20. Safety and immunogenicity of a Vi-DT typhoid conjugate vaccine: Phase I trial in Healthy Filipino adults and children.
    Capeding MR, Teshome S, Saluja T, Syed KA, Kim DR, Park JY, Yang JS, Kim YH, Park J, Jo SK, Chon Y, Kothari S, Yang SY, Ham DS, Ryu JH, Hwang HS, Mun JH, Lynch JA, Kim JH, Kim H, Excler JL, Sahastrabuddhe S.
    Vaccine; 2018 Jun 18; 36(26):3794-3801. PubMed ID: 29776750
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.